Case | Diagnosis | CRA 1 | CRA 2 | Consultant 1 | Consultant 2 |
J | AML prior to HSCT | Immunomediated | Immunomediated | Immunomediated | Immunomediated |
M | ATRT | Acute symptomatic intracranial haemorrhage | Acute symptomatic intracranial haemorrhage | Not reported | Acute symptomatic intracranial haemorrhage |
V | AML | Infection | Infection | Infection | Infection |
X | B cell ALL | Acute symptomatic intracranial haemorrhage | Acute symptomatic intracranial haemorrhage | Infection | Infection |
Y | T cell ALL | Respiratory | Infection | Acute symptomatic intracranial haemorrhage | Infection |
Z | B cell ALL | Respiratory | Infection | Respiratory | Infection |
AA | B cell ALL | Infection | Infection | Infection | Infection |
AB | Ependymoma | Not reported | Infection | Not reported | Infection |
AC | T cell ALL | Worsening symptomatic graft versus host disease | Worsening symptomatic graft versus host disease | Worsening symptomatic graft versus host disease | Acute symptomatic pulmonary haemorrhage |
AD | B cell ALL post-HSCT | Unclear | Difficult case | Worsening symptomatic graft versus host disease | Acute kidney Injury |
Bold font=probable causes of death.
ALL, acute lymphoblastic leukaemia; AML, acute myeloid lukemia; ATRT, atypical teratoid rhabdoid tumour; CRA, clinical research associates; HSCT, haematopoietic stem cell transplant; TRM, treatment-related mortality.